Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0 % AzaSite Compared to Vehicle in the Treatment of Bacterial Conjunctivitis
Brief Summary: The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either 1.0 % AzaSite or Vehicle. Three visits will be required for this study.


Options:
A: Inclusion Criteria:

* Diagnosed with bacterial conjunctivitis in 1 or both eyes;
* Able to understand and sign an informed consent form. If subject is \<18 years of age, the informed consent must be understood and signed by the subject's legally authorized representative;
* Agrees to comply with the visit schedule and other requirements of the study;
* Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

* Signs and symptoms of bacterial conjunctivitis for longer than 4 days prior to Day 1;
* Presence of concomitant viral infection;
* Infants with ophthalmia neonatorum of gonococcal, Chlamydia, herpetic or chemical origin;
* Infants whose birth mothers had any sexually transmitted disease within 1 month prior to delivery;
* Infants undergoing treatment for retinopathy of prematurity;
* Contact lens wear during the course of the study;
* Only 1 sighted eye or vision in either eye not correctable to 0.6 logMAR units (20/80) or better;
* Use of medications, as specified in the protocol;
* Any systemic or ocular disease or disorder, complicating factors or structural abnormality that could negatively affect the conduct or outcome of the study;
* Known or suspected allergy or hypersensitivity to fluoroquinolones;
* Pregnant, lactating, or of childbearing potential and not using adequate birth control to prevent pregnancy;
* Other protocol-specified exclusion criteria may apply.
B: Inclusion Criteria:

* Subjects who are at least one year of age.
* Subjects who have a clinical diagnosis of acute bacterial conjunctivitis.
* Subjects who are willing to discontinue contact lens wear for the duration of the study.

Exclusion Criteria:

* Subjects who have any uncontrolled systemic disease or debilitating disease.
* Subjects with known sensitivity or contraindications to besifloxacin, fluoroquinolones or any ingredients in study drugs.
* Subjects who are expected to require treatment with any disallowed medications.
C: Inclusion Criteria:

* Must have a diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge and redness in at least one eye.
* Females of childbearing potential must utilized reliable contraceptive methods and have a negative pregnancy test.

Exclusion Criteria:

* Pregnant or nursing females.
* Known hypersensitivity to fluoroquinolones or to any of the study ingredients.
* Use of any antibiotic within 72 hours of treatment.
* Any disease or condition that could interfere with the safety and efficacy evaluations of the study medications.
* Participation in an ophthalmic drug or device research study within 30 days prior to entry into the study.
D: Inclusion Criteria:

* Male or female subject, of any race, who is at least 1 year of age.
* Subjects must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit mucopurulent or purulent conjunctival discharge (crusty or sticky eyelids, globular and yellow discharge) and redness in at least one eye.
* The symptoms of bacterial conjunctivitis must be present for 3 days (approximately 72 hours) or less.
* Must be willing to discontinue contact lens wear for the duration of the study.

Exclusion Criteria:

* Any uncontrolled, systemic, debilitating disease.
* Use of topical ophthalmic solutions including tear substitutes within 2 hours before and during the study.
* Use of any topical ophthalmic anti-inflammatory agents within 48 hours before and during the study.
* Any active upper respiratory tract infection.
* Pregnant or nursing females.
* Use of any antibiotic (topical or systemic) within 72 hours of enrollment

Answer: D